Transplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell TransplantationPeripheral Blood Stem Cell TransplantationAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyTransplantation, HomologousTreatment OutcomeTransplantation ConditioningMultiple MyelomaCyclophosphamideMelphalanSalvage TherapyLymphoma, Non-HodgkinRemission InductionBone Marrow TransplantationStem CellsDisease-Free SurvivalAntineoplastic AgentsLiver TransplantationEtoposideHodgkin DiseaseRecurrenceMyeloablative AgonistsCytarabineGraft vs Host DiseaseCarmustineSurvival RateHematopoietic Stem Cell MobilizationThiotepaBone Marrow PurgingSurvival AnalysisHematologic NeoplasmsVincristineGraft SurvivalWhole-Body IrradiationRetrospective StudiesKidney TransplantationLymphoma, Mantle-CellHematopoietic Stem CellsBusulfanAmyloidosisDoxorubicinPrognosisFollow-Up StudiesDexamethasoneBoronic AcidsPyrazinesTime FactorsAntigens, CD34Antibodies, Monoclonal, Murine-DerivedAntineoplastic Agents, AlkylatingLymphoma, FollicularAutograftsTransplantation ChimeraMesenchymal Stem Cell TransplantationTissue DonorsLymphoma, T-Cell, PeripheralCell TransplantationThalidomideIfosfamideChemotherapy, AdjuvantGranulocyte Colony-Stimulating FactorHeart TransplantationLeukapheresisCord Blood Stem Cell TransplantationPrednisoneLymphomaInduction ChemotherapyPodophyllotoxinLung TransplantationNeoplasm, ResidualLeukemia, Myeloid, AcuteLymphoma, Large B-Cell, DiffuseImmunosuppressive AgentsMaintenance ChemotherapyDose-Response Relationship, DrugHistocompatibility TestingMyelodysplastic SyndromesOrgan TransplantationTransplantation ImmunologyGraft RejectionProspective StudiesLymphoma, B-CellEmbryonic Stem CellsBlood Transfusion, AutologousMitoxantroneIdarubicinEnteropathy-Associated T-Cell LymphomaNeoplasms, Second PrimaryLeukemia, Plasma CellCisplatinBlood Component RemovalCarboplatinInfusions, SpinalAntibodies, MonoclonalDrug Administration ScheduleAdult Stem CellsHistocompatibilityFeasibility Studies